536565 — Novelix Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

FinancialsHighly SpeculativeMicro CapMomentum Trap

Annual income statement for Novelix Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	R2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	92.4	8.43	14	42.2	307
Cost of Revenue
Gross Profit	6.76	0.35	0.524	3.87	11.4
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	132	11.9	19.8	45.1	306
Operating Profit	-40.1	-3.45	-5.74	-2.86	1.07
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-37.5	-15.7	-0.585	0.213	1.23
Provision for Income Taxes
Net Income After Taxes	-37.6	-15.6	-0.599	0.104	0.845
Minority Interest
Net Income Before Extraordinary Items
Net Income	-37.4	-15.6	-0.599	0.104	0.845
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-37.4	-15.6	-0.599	0.104	0.845
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-4.62	-1.91	-0.074	-0.016	0.085